The Latest Lung Cancer Journal Articles
Keep up to date with the latest in lung cancer. Check out the latest lung cancer articles from leading medical journals in a single view, helping you discover relevant articles quickly and easily
- Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations.Selpercatinib (LOXO-292) and pralsetinib (BLU-667) are highly potent RET-selective protein tyrosine kinase inhibitors (TKIs) for treating advanced RET-altered thyroid cancers and non-small cell lung cancer (NSCLC). It is critical to analyze RET mutants resistant to these drugs and unravel the molecular basis to improve patient outcomes.Cell-free DNAs (cfDNAs) were analyzed in a RET-mutant medullary thyroid […]
- Intermittent schedules of the oral RAF-MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study.CH5126766 (also known as VS-6766, and previously named RO5126766), a novel MEK-pan-RAF inhibitor, has shown antitumour activity across various solid tumours; however, its initial development was limited by toxicity. We aimed to investigate the safety and toxicity profile of intermittent dosing schedules of CH5126766, and the antitumour activity of this drug in patients with solid […]
- The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers.KRAS is mutated in ∼90% of pancreatic ductal adenocarcinomas (PDAC), ∼35% of colorectal cancers (CRC) and ∼20% of non-small-cell lung cancers (NSCLC). There has been recent progress in targeting G12CKRAS specifically, but therapeutic options for other mutant forms of KRAS are limited, largely because the complexity of downstream signaling and feedback mechanisms mean that targeting […]
- Comparing Nanoparticle Polymeric Micellar Paclitaxel and Solvent-based Paclitaxel as First-line Treatment of Advanced Non-Small Cell Lung Cancer: An Open-label, Randomized, Multicenter, Phase III Trial.Polymeric micellar paclitaxel (pm-Pac) is a novel Cremophor EL (CrEL)-free, nanoparticle micellar formulation of paclitaxel. We aimed to compare the efficacy and safety between pm Pac plus cisplatin and sb-Pac (solvent-based paclitaxel) plus cisplatin in advanced non-small cell lung cancer (NSCLC).448 stage IIIB to IV NSCLC patients were randomly assigned (2:1) to receive six 3-week […]
- Validation of Lung EpiCheck®, a novel methylation-based blood assay, for the detection of lung cancer in European and Chinese high-risk individuals.Lung cancer screening reduces mortality. We aim to validate the performance of Lung EpiCheck®, a 6-marker panel methylation-based plasma test, in the detection of lung cancer in European and Chinese samples.A case-control European training set (102 lung cancer cases/265 controls) was used to define the panel and algorithm. Two cut-offs were selected, low cut-off (LCO) […]
- Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol.The Lung Cancer Master Protocol (Lung-MAP; S1400) is a completed biomarker-driven master protocol designed to address an unmet need for better therapies for squamous non-small-cell lung cancer. Lung-MAP (S1400) was created to establish an infrastructure for biomarker screening and rapid regulatory intent evaluation of targeted therapies and was the first biomarker-driven master protocol initiated with […]
- Circ_0001421 facilitates glycolysis and lung cancer development by regulating miR-4677-3p/CDCA3.Lung cancer (LC) is a malignant tumor originating in the bronchial mucosa or gland of the lung. Circular RNAs (circRNAs) are proved to be key regulators of tumor progression. However, the regulatory effect of circ_0001421 on lung cancer tumorigenesis remains unclear.The expression levels of circ_0001421, microRNA-4677-3p (miR-4677-3p) and cell division cycle associated 3 (CDCA3) were […]
- Formalin fixation for optimal concordance of programmed death-ligand 1 immunostaining between cytologic and histologic specimens from patients with non-small cell lung cancer.Immunohistochemical staining of programmed death-ligand 1 (PD-L1) is used to determine which patients with non-small cell lung cancer (NSCLC) may benefit most from immunotherapy. Therapeutic management of many patients with NSCLC is based on cytology instead of histology. In this study, concordance of PD-L1 immunostaining between cytology cell blocks and their histologic counterparts was analyzed. […]
- Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials.Radiotherapy might augment systemic antitumoral responses to immunotherapy. In the PEMBRO-RT (phase 2) and MDACC (phase 1/2) trials, patients with metastatic non-small-cell lung cancer were randomly allocated immunotherapy (pembrolizumab) with or without radiotherapy. When the trials were analysed individually, a potential benefit was noted in the combination treatment arm. However, owing to the small sample […]
- Psychological outcomes of low-dose CT lung cancer screening in a multisite demonstration screening pilot: the Lung Screen Uptake Trial (LSUT).Previous studies of psychological burden in low-dose CT (LDCT) lung cancer screening trials may lack generalisability due to participation bias and control arms having elevated distress.Current and former smokers (n=787, aged 60-75) within a real-world screening demonstration pilot completed measures of lung cancer worry at three time points (T0: appointment, T1: next day, T2: 3 […]
- Liverpool Lung Project lung cancer risk stratification model: calibration and prospective validation.Early detection of lung cancer saves lives, as demonstrated by the two largest published low-dose CT screening trials. Optimal implementation depends on our ability to identify those most at risk.Version 2 of the Liverpool Lung Project risk score (LLPv2) was developed from case-control data in Liverpool and further adapted when applied for selection of subjects […]
- Role of unfolded proteins in lung disease.The lungs are exposed to a range of environmental toxins (including cigarette smoke, air pollution, asbestos) and pathogens (bacterial, viral and fungal), and most respiratory diseases are associated with local or systemic hypoxia. All of these adverse factors can trigger endoplasmic reticulum (ER) stress. The ER is a key intracellular site for synthesis of secretory […]
- Solitary pulmonary nodule imaging approaches and the role of optical fibre-based technologies.Solitary pulmonary nodules (SPNs) are a clinical challenge, given there is no single clinical sign or radiological feature that definitively identifies a benign from a malignant SPN. The early detection of lung cancer has a huge impact on survival outcome. Consequently, there is great interest in the prompt diagnosis, and treatment of malignant SPNs. Current […]
- Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH).Therapeutically actionable molecular alterations are widely distributed across cancer types. The National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH) trial was designed to evaluate targeted therapy antitumor activity in underexplored cancer types. Tumor biopsy specimens were analyzed centrally with next-generation sequencing (NGS) in a master screening protocol. Patients with a tumor molecular alteration addressed […]
- Association Between a National Insurer’s Pay-for-Performance Program for Oncology and Changes in Prescribing of Evidence-Based Cancer Drugs and Spending.Cancer drug prescribing by medical oncologists accounts for the greatest variation in practice and the largest portion of spending on cancer care. We evaluated the association between a national commercial insurer’s ongoing pay-for-performance (P4P) program for oncology and changes in the prescribing of evidence-based cancer drugs and spending.We conducted an observational difference-in-differences study using administrative […]
- Randomized Trial of Afatinib Plus Cetuximab Versus Afatinib Alone for First-Line Treatment of EGFR-Mutant Non-Small-Cell Lung Cancer: Final Results From SWOG S1403.The irreversible ErbB family tyrosine kinase inhibitor (TKI) afatinib plus the EGFR monoclonal antibody cetuximab was previously shown to overcome resistance to EGFR TKIs. We studied whether the combination of afatinib plus cetuximab compared with afatinib alone would improve progression-free survival (PFS) in patients with treatment-naive EGFR-mutant non-small-cell lung cancer (NSCLC) by preventing or delaying […]
- Trends in mediastinal nodal staging and its impact on unforeseen N2 and survival in lung cancer.Guidelines for invasive mediastinal nodal staging in resectable NSCLC have changed over the years. The aims of this study were to describe trends in invasive staging and unforeseen N2 (uN2) and to assess a potential effect on overall survival (OS).A nationwide Dutch cohort study included all clinical stage IA-IIIB NSCLC patients primarily treated by surgical […]
- Liquid biopsy for lung cancer screening: Usefulness of circulating tumor cells and other circulating blood biomarkers.Screening for lung cancer has become a reality in certain countries, most notably the United States, but its implementation currently is under discussion and not established in many nations, including France. Screening for lung cancer currently is proposed using a low-dose computed tomography scanner. However, this approach lacks sensitivity and specificity, and could be improved […]
- Mechanisms of Resistance to Selective RET Tyrosine Kinase Inhibitors in RET Fusion-Positive Non-Small Cell Lung Cancer.Rearranged during transfection (RET) gene fusions are a validated target in non-small cell lung cancer (NSCLC). RET-selective inhibitors selpercatinib (LOXO-292) and pralsetinib (BLU-667) recently demonstrated favorable antitumor activity and safety profiles in advanced RET fusion-positive NSCLC, and both have received approval by the US Food and Drug Administration for this indication. Insights into mechanisms of […]
- Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC.The efficacy and safety of the anti-programmed death ligand 1 (PD-L1) monoclonal antibody atezolizumab, as compared with those of platinum-based chemotherapy, as first-line treatment for patients with metastatic non-small-cell lung cancer (NSCLC) with PD-L1 expression are not known.We conducted a randomized, open-label, phase 3 trial involving patients with metastatic nonsquamous or squamous NSCLC who had […]
- Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC.The efficacy and safety of the anti-programmed death ligand 1 (PD-L1) monoclonal antibody atezolizumab, as compared with those of platinum-based chemotherapy, as first-line treatment for patients with metastatic non-small-cell lung cancer (NSCLC) with PD-L1 expression are not known.We conducted a randomized, open-label, phase 3 trial involving patients with metastatic nonsquamous or squamous NSCLC who had […]
- Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial.Non-small-cell lung cancer (NSCLC) is terminal in most patients with locally advanced stage disease. We aimed to assess the antitumour activity and safety of neoadjuvant chemoimmunotherapy for resectable stage IIIA NSCLC.This was an open-label, multicentre, single-arm phase 2 trial done at 18 hospitals in Spain. Eligible patients were aged 18 years or older with histologically […]
- Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer.Osimertinib is standard-of-care therapy for previously untreated epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC). The efficacy and safety of osimertinib as adjuvant therapy are unknown.In this double-blind, phase 3 trial, we randomly assigned patients with completely resected EGFR mutation-positive NSCLC in a 1:1 ratio to receive either osimertinib (80 mg once […]
- KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors.No therapies for targeting KRAS mutations in cancer have been approved. The KRAS p.G12C mutation occurs in 13% of non-small-cell lung cancers (NSCLCs) and in 1 to 3% of colorectal cancers and other cancers. Sotorasib is a small molecule that selectively and irreversibly targets KRASG12C.We conducted a phase 1 trial of sotorasib in patients with […]
- Distinguishing smoking related lung disease phenotypes via imaging and molecular features.Chronic tobacco smoke exposure results in a broad range of lung pathologies including emphysema, airway disease and parenchymal fibrosis as well as a multitude of extra-pulmonary comorbidities. Prior work using computed tomography imaging has identified several clinically relevant subgroups of smoking related lung disease, but these investigations have generally lacked organ specific molecular correlates.Can computed […]
- Effects of Random Measurement Error on Lung Cancer Screening Decisions:: A Retrospective-Cohort-Based Microsimulation Study.Self-reported tobacco pack-year history plays a large role in decisions about low-dose computed tomography (CT) lung cancer screening yet is challenging to measure accurately.To what extent does random measurement error in pack-year information impact screening decisions and screening effectiveness?and Methods: Retrospective cohort study of 10,449 patients with pack-year history documented at least twice between 10/2013-7/2017, […]
- NRG1 fusion-driven tumors: biology, detection and the therapeutic role of afatinib and other ErbB-targeting agents.Oncogenic gene fusions are hybrid genes that result from structural DNA rearrangements, leading to deregulated activity. Fusions involving the neuregulin-1 gene (NRG1) result in ErbB-mediated pathway activation and therefore present a rational candidate for targeted treatment. The most frequently reported NRG1 fusion is CD74-NRG1, which most commonly occurs in patients with invasive mucinous adenocarcinomas (IMA) […]
- Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: CheckMate 153.Limited data exist on the optimal duration of immunotherapy, including for non-small-cell lung cancer (NSCLC). We present an exploratory analysis of CheckMate 153, a largely community-based phase IIIb/IV study, to evaluate the impact of 1-year fixed-duration versus continuous therapy on the efficacy and safety of nivolumab.Patients with previously treated advanced NSCLC received nivolumab monotherapy (3 […]
- Current and future trends in non-small cell lung cancer biomarker testing: The American experience.Biomarker testing in patients with advanced stage non-small cell lung cancer provides essential information that can be used to select the most appropriate therapy. The regular updates of guideline recommendations reflect the growing number of biomarkers that must be assessed, and as such signal the shift from single-gene assays to more comprehensive genomic profiling using […]
- Predictive molecular pathology of lung cancer in Germany with focus on gene fusion testing: Methods and quality assurance.Predictive molecular testing has become an important part of the diagnosis of any patient with lung cancer. Using reliable methods to ensure timely and accurate results is inevitable for guiding treatment decisions. In the past few years, parallel sequencing has been established for mutation testing, and its use is currently broadened for the detection of […]
- Lesson of the month: novel method to quantify neutrophil uptake in early lung cancer using SPECT-CT.Neutrophils play an important role in the lung tumour microenvironment. We hypothesised that radiolabelled neutrophils coupled to single-photon emission CT (SPECT) may non-invasively quantify neutrophil uptake in tumours from patients with non-small cell lung cancer. We demonstrated increased uptake of radiolabelled neutrophils from the blood into tumours compared with non-specific uptake using radiolabelled transferrin. Moreover, […]
- Using Geospatial Analysis to Evaluate Access to Lung Cancer Screening in the United States.Screening current and former heavy smokers aged 55-80 years for lung cancer with low dose chest CT has been recommended by the USPSTF since 2013. Although the number of screening facilities in the US has increased, screening uptake has been slow. To better understand the slow screening uptake, we evaluated geographic access to screening facilities […]
- Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial.Topotecan is currently the only drug approved in Europe in a second-line setting for the treatment of small-cell lung cancer. This study investigated whether the doublet of carboplatin plus etoposide was superior to topotecan as a second-line treatment in patients with sensitive relapsed small-cell lung cancer.In this open-label, randomised, phase 3 trial done in 38 […]
- Lung cancer and molecular testing in small biopsies versus cytology: The Logics of Worlds.The 8th Annual National Molecular Cytopathology Meeting, held in Naples, Italy, on December 2 to 3, 2019, addressed updates in diagnostic cytopathology and molecular classifications and specifically focused on lung cancer biomarker testing in cytology samples. Lung cancer continues to be the most commonly diagnosed noncutaneous malignancy in the world. In the majority of patients, […]
- Predictive molecular pathology in non-small cell lung cancer in France: The past, the present and the perspectives.The advent of molecular targets for novel therapeutics in oncology, notably for non-small cell lung carcinoma (NSCLC), led the French National Cancer Institute (INCa) to establish a national network of 28 hospital Molecular Genetics Centers for Cancer (MGCC) in 2007. In each University in France, laboratories were established to develop molecular biology testing to evaluate […]
- “How to Review Post-lobectomy Posteroanterior Chest Radiographs”.Lung cancer is currently the most common malignancy in the world. A lobectomy is the gold standard of care for most patients with an operable lung cancer and accounts for 60-70% of lung resection. The chest radiograph may appear normal after a lobectomy, particularly in uncomplicated cases. However, lobectomy usually leaves the surgical staples at […]
- Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer.Among patients with non-small-cell lung cancer (NSCLC), MET exon 14 skipping mutations occur in 3 to 4% and MET amplifications occur in 1 to 6%. Capmatinib, a selective inhibitor of the MET receptor, has shown activity in cancer models with various types of MET activation.We conducted a multiple-cohort, phase 2 study evaluating capmatinib in patients […]
- Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer.Among patients with non-small-cell lung cancer (NSCLC), MET exon 14 skipping mutations occur in 3 to 4% and MET amplifications occur in 1 to 6%. Capmatinib, a selective inhibitor of the MET receptor, has shown activity in cancer models with various types of MET activation.We conducted a multiple-cohort, phase 2 study evaluating capmatinib in patients […]
- Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis.In AURA3 (NCT02151981), osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), significantly prolonged progression-free survival and improved response in patients with EGFR T790M advanced non-small-cell lung cancer (NSCLC) and progression on prior EGFR-TKI treatment. We report the final AURA3 overall survival (OS) analysis.Adult patients were randomized 2:1 to osimertinib (80 mg […]
- Genetically raised serum bilirubin levels and lung cancer: a cohort study and Mendelian randomisation using UK Biobank.Moderately raised serum bilirubin levels are associated with lower rates of lung cancer, particularly among smokers. It is not known whether these relationships reflect antioxidant properties or residual confounding.This study aimed to investigate potential causal relationships between serum total bilirubin and lung cancer incidence using one-sample Mendelian randomisation (MR) and UK Biobank.We instrumented serum total […]
- Functional assessment and phenotypic heterogeneity of
SFTPA1
and
SFTPA2
mutations in interstitial lung diseases and lung cancer.Interstitial lung diseases (ILD) can be caused by mutations in the SFTPA1 and SFTPA2 genes, which encode the surfactant protein complex (SP)-A. Only 11 SFTPA1/2 mutations have so far been reported worldwide, of which 5 have been functionally assessed. In the framework of ILD molecular diagnosis, we identified 14 independent patients with pathogenic SFTPA1 or […]
- Genetically raised serum bilirubin levels and lung cancer: a cohort study and Mendelian randomisation using UK Biobank.Moderately raised serum bilirubin levels are associated with lower rates of lung cancer, particularly among smokers. It is not known whether these relationships reflect antioxidant properties or residual confounding.This study aimed to investigate potential causal relationships between serum total bilirubin and lung cancer incidence using one-sample Mendelian randomisation (MR) and UK Biobank.We instrumented serum total […]
- Functional assessment and phenotypic heterogeneity of
SFTPA1
and
SFTPA2
mutations in interstitial lung diseases and lung cancer.Interstitial lung diseases (ILD) can be caused by mutations in the SFTPA1 and SFTPA2 genes, which encode the surfactant protein complex (SP)-A. Only 11 SFTPA1/2 mutations have so far been reported worldwide, of which 5 have been functionally assessed. In the framework of ILD molecular diagnosis, we identified 14 independent patients with pathogenic SFTPA1 or […]
- Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: A report from the ESMO Precision Medicine Working Group.Next-generation sequencing (NGS) allows sequencing a high number of nucleotides in a short time frame at an affordable cost. While this technology has been widely implemented, there are no recommendations from scientific societies about their use in oncology practice. The European Society for Medical Oncology (ESMO) is proposing three levels of recommendations for the use […]
- Pulmonary epithelial-myoepithelial carcinoma without AKT1, HRAS or PIK3CA mutations: a case report.Pulmonary epithelial-myoepithelial carcinoma is a rare subtype of lung cancer. Because of its rarity, the molecular information on this carcinoma is insufficient.We report a case of pulmonary epithelial-myoepithelial carcinoma without AKT1, HRAS or PIK3CA mutations in a 76-year-old woman. Computed tomography revealed a tumor located in the left lower lung. Thoracoscopic left lower lobectomy was […]
- Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer.RET fusions are oncogenic drivers in 1 to 2% of non-small-cell lung cancers (NSCLCs). In patients with RET fusion-positive NSCLC, the efficacy and safety of selective RET inhibition are unknown.We enrolled patients with advanced RET fusion-positive NSCLC who had previously received platinum-based chemotherapy and those who were previously untreated separately in a phase 1-2 trial […]
- Computed Tomography Imaging and Comorbidities in Chronic Obstructive Pulmonary Disease: Beyond Lung Cancer Screening.Comorbidities significantly contribute to morbidity, mortality, and health care costs in individuals with chronic obstructive pulmonary disease (COPD). Comorbidity prevalence does not always correlate with lung disease severity and the elevated risk of certain comorbidities is often independent of shared risk factors such as tobacco burden. While COPD management guidelines recognize the importance of identifying […]
- Survival After Detection of Stage I Lung Cancer by Screening in the National Lung Screening Trial.There is limited information about survival of Stage I lung cancer diagnosed by screening.What was the survival rate of screen-detected Stage I lung cancer in the National Lung Screening Trial (NLST), and was it affected by screening method, patient or tumor characteristics, or treatment method?The study cohort consisted of all NLST participants with screen-detected Stage […]
- How Health Care Organizations Implement Shared Decision Making When It Is Required for Reimbursement: The Case of Lung Cancer Screening.The Centers for Medicare and Medicaid Services stipulated shared decision making (SDM) counseling as a prerequisite to lung cancer screening (LCS) reimbursement, despite well-known challenges implementing SDM in practice.How have health care organizations implemented SDM for LCS?and Methods: For this qualitative study, we used data from in-depth, semi-structured interviews with key informants directly involved in […]
- Chemotherapy and COVID-19 Outcomes in Patients With Cancer.Coronavirus-2019 (COVID-19) mortality is higher in patients with cancer than in the general population, yet the cancer-associated risk factors for COVID-19 adverse outcomes are not fully characterized.We reviewed clinical characteristics and outcomes from patients with cancer and concurrent COVID-19 at Memorial Sloan Kettering Cancer Center until March 31, 2020 (n = 309), and observed clinical […]
- The Effect of Advances in Lung-Cancer Treatment on Population Mortality.Lung cancer is made up of distinct subtypes, including non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC). Although overall mortality from lung cancer has been declining in the United States, little is known about mortality trends according to cancer subtype at the population level because death certificates do not record subtype information.Using data from […]
- Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial.Brigatinib, a next-generation anaplastic lymphoma kinase (ALK) inhibitor, demonstrated superior progression-free survival (PFS) and improved health-related quality of life (QoL) versus crizotinib in advanced ALK inhibitor-naive ALK-positive non-small cell lung cancer (NSCLC) at first interim analysis (99 events; median brigatinib follow-up, 11.0 months) in the open-label, phase III ALTA-1L trial (ClinicalTrials.gov identifier: NCT02737501). We report […]
- Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study.Poly (ADP-ribose) polymerase inhibitors combined with immunotherapy have shown antitumour activity in preclinical studies. We aimed to assess the safety and activity of olaparib in combination with the PD-L1-inhibitor, durvalumab, in patients with germline BRCA1-mutated or BRCA2-mutated metastatic breast cancer.The MEDIOLA trial is a multicentre, open-label, phase 1/2, basket trial of durvalumab and olaparib in […]
- Volume Pledge is Not Associated with Better Short-Term Outcomes After Lung Cancer Resection.We examined the relationship between short-term outcomes and hospitals and surgeons who met minimum volume thresholds for lung cancer resection based on definitions provided by the Volume Pledge. A secondary aim was to evaluate the volume-outcome relationship to determine alternative thresholds in the event the Volume Pledge was not associated with outcomes.We conducted a retrospective […]
- Lung Screen Uptake Trial: results from a single lung cancer screening round.The Lung Screen Uptake Trial tested a novel invitation strategy to improve uptake and reduce socioeconomic and smoking-related inequalities in lung cancer screening (LCS) participation. It provides one of the first UK-based ‘real-world’ LCS cohorts. Of 2012 invited, 1058 (52.6%) attended a ‘lung health check’. 768/996 (77.1%) in the present analysis underwent a low-dose CT […]
- Impact of the Percepta Genomic Classifier on Clinical Management Decisions in a Multicenter Prospective Study.The Percepta genomic classifier has been clinically validated as a complement to bronchoscopy for lung nodule evaluation. This study examines the impact on clinical management decisions of the Percepta result in patients with low/ intermediate risk lung nodules.We instituted a prospective “real world” registry across 35 U.S. centers to observe physician management of pulmonary nodules […]
- Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Results of the NCI-MATCH Trial Subprotocol H.BRAFV600 mutations are commonly found in melanoma and thyroid cancers and to a lesser degree in other tumor types. Subprotocol H (EAY131-H) of the NCI-MATCH platform trial sought to investigate the selective BRAF inhibitor dabrafenib and the MEK1/2 inhibitor trametinib in patients with solid tumors, lymphomas, or multiple myeloma whose tumors harbored a BRAFV600 mutation.EAY131-H […]
- An Enhanced Prognostic Score for Overall Survival of Patients with Cancer Derived from a large Real World Cohort.By understanding prognostic biomarkers, we gain insights into disease biology and may improve design, conduct, and data analysis of clinical trials and real world data. In this context, we used the Flatiron Health Electronic Health Record-derived de-identified database that provides treatment outcome and biomarker data from >280 oncology centers in the USA, organized into 17 […]
- Variation between multidisciplinary tumor boards in clinical staging and treatment recommendations for patients with locally advanced non-small cell lung cancer.Accurate diagnosis and staging is crucial to ensure uniform allocation to the optimal treatment modalities for non-small cell lung cancer (NSCLC), but may differ between multidisciplinary tumor boards (MDT). Discordance between clinical and pathological TNM-stage is particularly important for patients with locally advanced NSCLC (stage IIIA) because it may influence their chance of allocation to […]
- Earlier diagnosis of lung cancer in a randomised trial of an autoantibody blood test followed by imaging.The EarlyCDT-Lung test is a high specificity blood-based autoantibody biomarker that could contribute to predicting lung cancer risk. Here we report on the results of a phase IV biomarker evaluation of whether using the EarlyCDT-Lung test and any subsequent CT scanning to identify those at high risk of lung cancer reduces the incidence of patients […]